A multicenter, randomized, double-blind, parallel arm, 12-week study to evaluate the efficacy and safety of ezetimibe 10 mg when added to atorvastatin 10 mg versus titration to atorvastatin 20 mg and to 40 mg in elderly patients with hypercholesterolaemia at high risk for CHD

Trial Profile

A multicenter, randomized, double-blind, parallel arm, 12-week study to evaluate the efficacy and safety of ezetimibe 10 mg when added to atorvastatin 10 mg versus titration to atorvastatin 20 mg and to 40 mg in elderly patients with hypercholesterolaemia at high risk for CHD

Completed
Phase of Trial: Phase III

Latest Information Update: 05 May 2014

At a glance

  • Drugs Ezetimibe (Primary) ; Atorvastatin
  • Indications Coronary disorders; Hypercholesterolaemia; Hyperlipidaemia
  • Focus Therapeutic Use
  • Acronyms ZETELD
  • Sponsors Merck & Co
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Mar 2010 Results have been published in the American Journal of Cardiology.
    • 13 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top